Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...

BeWell, New Mexico’s health insurance marketplace, works to help people who don’t qualify for Medicaid or Medicare find ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...

Fewer and fewer twins and triplets are being born through IVF in Australia, bringing IVF and overall Australian multiple ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).

According to the posting, 6,523 patients had names, dates of birth, and medical information compromised. In response to CBS News Texas inquiries, a Parkland Health spokesperson provided the ...

The new procedure not only slashes the hours needed on the operating table, but patient recovery time, as well. Doreen Adams underwent the unique procedure after a previous craniotomy to remove ...